Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Top Cited Papers
Open Access
- 12 November 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 24 (1), 22-32
- https://doi.org/10.1038/leu.2009.236
Abstract
Immunomodulatory drugs (IMiDs) are thalidomide analogues, which possess pleiotropic anti-myeloma properties including immune-modulation, anti-angiogenic, anti-inflammatory and anti-proliferative effects. Their development was facilitated by an improved understanding in myeloma (MM) biology and initiated a profound shift in the therapeutic approach towards MM. Despite the diverse effects of IMiDs in vitro, the relative contribution of each effect towards their ultimate anti-MM activity is still unclear. Based on in vitro data, it appears that anti-proliferative effects and downregulation of crucial cytokines are their most important anti-MM attributes. Although the co-stimulatory effects on T and NK cells have been heralded as a unique and important property of IMiDs towards enhancing anti-MM immune activity, these in vitro effects have yet to be firmly corroborated in vivo. Much is yet to be elucidated regarding the complex interplay of immunomodulatory cytokines that occurs in vivo, which ultimately dictates the net effects of IMiDs in MM—the understanding of which is necessary to facilitate optimal manipulation of these drugs in future MM management.Keywords
This publication has 96 references indexed in Scilit:
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cellsBlood, 2008
- First thalidomide clinical trial in multiple myeloma: a decadeBlood, 2008
- Lenalidomide inhibits the malignant clone and up-regulates theSPARCgene mapping to the commonly deleted region in 5q− syndrome patientsProceedings of the National Academy of Sciences of the United States of America, 2007
- Tregs and rethinking cancer immunotherapyJCI Insight, 2007
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myelomaBlood, 2006
- Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's LymphomaCancer Research, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Natural Killer Cells Produce T Cell–Recruiting Chemokines in Response to Antibody-Coated Tumor CellsCancer Research, 2006
- Immunomodulatory Drugs (IMiDs) Increase the Production of IL-2 from Stimulated T Cells by Increasing PKC-θ Activation and Enhancing the DNA-Binding Activity of AP-1 but Not NF-κB, OCT-1, or NF-ATJournal of Interferon & Cytokine Research, 2005
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994